



PRESS RELEASE

## **Bulletin from Moberg Pharma's Extraordinary General Meeting on December 1<sup>st</sup>, 2020**

STOCKHOLM, December 1<sup>st</sup>, 2020. Moberg Pharma AB (publ)'s (OMX: MOB) ("Moberg Pharma" or the "Company") Extraordinary General Meeting took place today. The Extraordinary General Meeting resolved as set out below.

### **Approval of the Board of Directors decision on a rights issue**

The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to approve the Board of Directors' resolution on 6 November 2020 to issue units consisting of ordinary shares and warrants with preferential rights for the current shareholders in the Company. According to the final terms for the rights issue determined by the Board of Directors, as announced on 27 November 2020, each share in the Company held on the record date for participation in the rights issue, 3 December 2020, entitles to seven (7) unit rights and six (6) unit rights entitles to subscription for one new ordinary share. In aggregate, up to 23,175,576 units may be issued. Each unit consists of one (1) ordinary share and one (1) free of charge warrant, which entails that up to 23,175,576 new ordinary shares and up to 23,175,576 new warrants may be issued.

The subscription price has been set to SEK 6.47 per unit, corresponding to a subscription price of 6.47 per ordinary share. The Company is expected to receive issue proceeds of approximately SEK 150 million before transaction costs. The subscription period will occur during the period 7 December 2020 – 21 December 2020, or such later date as decided by the Board of Directors. The rights issue entails that the Company's share capital can be increased by a maximum of SEK 3,476,336.40 through the issue of not more than 34,763,364 new ordinary shares, provided that all warrants are exercised for subscription of ordinary shares. Additional information regarding the rights issue will be included in the prospectus which is expected to be published on 3 December 2020.

### **Transfer of assets from Moberg Pharma to subsidiary (related party transaction)**

The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to approve the Company's transfer of the business BupiZenge® to the subsidiary Grebom 2020 AB (under name change to OncoZenge AB) ("OncoZenge").

### **Distribution of shares**

The Extraordinary General Meeting resolved, in accordance with the Board of Directors' proposal, to distribute the Company's shares in the subsidiary OncoZenge to the Company's shareholders. The resolution entails a distribution of all the Company's shares in OncoZenge. Ten (10) shares in the Company as of the record date for the distribution entitles to one (1) share in OncoZenge. Moberg Pharma holds 554,746 own shares, which will not be entitled to the distribution of shares in OncoZenge. The Board of Directors were authorised to decide the record date for the distribution, with a contemplated record date in January/February 2021.

### **Post voting procedure**

To prevent the spread of the virus that causes Covid-19, the Extraordinary General Meeting was conducted via a post voting procedure and thus without physical presence of shareholders, proxies or external parties.

### **Minutes from the meeting and complete resolutions**

The minutes from the Extraordinary General Meeting will be made available at the Company and on the Company's website, [www.mobergpharma.com](http://www.mobergpharma.com).



**For additional information, please contact:**

Anna Ljung, CEO, telephone: +46 70 766 60 30, e-mail: [anna.ljung@mobergpharma.se](mailto:anna.ljung@mobergpharma.se)

Mark Beveridge, Vice President Finance, telephone: +46 76 805 82 88, e-mail: [mark.beveridge@moberpharma.se](mailto:mark.beveridge@moberpharma.se)

**About this information**

The information was submitted for publication at 1.30 p.m. on December 1<sup>st</sup>, 2020 through the contact persons above.

**About Moberg Pharma, [www.mobergpharma.com](http://www.mobergpharma.com)**

Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The company's main asset, MOB-015, is a novel topical treatment for onychomycosis, with recently completed phase 3 trials in more than 800 patients. The pipeline also includes the late-stage asset BUPI for pain relief in oral mucositis. Clinical data generated for both assets indicate they have the potential to become market leaders in their respective niches. Moberg Pharma is headquartered in Stockholm and the company's shares are listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).